… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … 1/2 clinical trial of QR-421a, an investigational RNAtherapy. The Stellar trial is a randomized, single ascending …
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit and the ARVO 2022 Annual Meeting … to focus on accelerating the development of Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple … to changing lives through the creation of transformative RNA therapies, today reported its financial and operating … were presented at the Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Presentation title: A different type of genetic therapy: correcting a defective gene using antisense …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … followed by a live Q&A session. Session: Stem cells/gene therapy/transplantation Date: May 6, 2021 at 5:15pm EDT …
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will pres
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … QR-421a QR-421a is a first-in-class investigational RNAtherapy designed to address the underlying cause of vision …